NCT07264816 2026-03-05
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Sanofi
Sichuan Cancer Hospital and Research Institute
Affiliated Hospital of Hebei University
Providence Health & Services